Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?

Sarah Marmol, Matthew Feldman, Carlos Singer, Jason Margolesky

Research output: Contribution to journalArticlepeer-review


The best practice for the initiation of symptomatic motor treatment for Parkinson’s disease is an ongoing topic of debate. Fueled by interpretation of the results of the LEAP and MED Parkinson’s disease studies, many practitioners opt for early initiation of levodopa formulations, avoiding dopamine agonists to circumvent potential deleterious side effects, namely impulse control disorder. Compared with levodopa, monoamine oxidase inhibitors may lack necessary potency. Ignored in this academic debate is another therapeutic option for patients with Parkinson’s disease requiring treatment initiation: amantadine. Amantadine was first reported effective in the treatment of Parkinson’s disease in 1969 and several studies were published in the 1970s supporting its efficacy. Currently, amantadine is mainly utilized as an add-on therapy to mitigate levodopa-related dyskinesia and, more recently, new long-acting amantadine formulations have been developed, with new indications to treat motor fluctuations. Amantadine has not been reported to cause dyskinesia and is rarely implicated in impulse control disorder.

Original languageEnglish (US)
Pages (from-to)1141-1152
Number of pages12
JournalCNS Drugs
Issue number11
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?'. Together they form a unique fingerprint.

Cite this